NCR Corporation announces the resolution of the Michigan Kalamazoo River environmental cleanup and related Superfund litigation by entering in to a definitive consent decree with the United States Government and the State of Michigan, under which the company expects to conclude the longstanding matter. The decree is subject to court approval. Upon approval by the court, the decree will bring to an end a set of complex litigations that commenced in 2010. In particular the settlement will provide contribution protection to NCR that will foreclose Superfund litigation claims brought against it by the other companies that themselves had contributed to the pollution of the river. The cleanup work is expected to be performed over the next 20 years. NCR will seek significant contribution from NCR's indemnitors as it has in the past for other projects.

RH announced that Chairman & Chief Executive Officer Gary Friedman sold an aggregate of 500,000 shares of RH common stock from December 9, 2019 through December 11, 2019 consisting of an option to purchase 100,000 shares, and 400,000 shares of common stock that Friedman owned outright. Friedman reported that the current sale of shares was made in order to fund a final payment obligation due under a marital dissolution agreement; the acquisition and improvement of real estate for a personal residence; and the repayment of outstanding balances under personal line of credit borrowings. The current sale represented approximately 6.9% of Friedman's aggregate ownership stake in RH. Following this sale, Friedman retains beneficial ownership of 6,730,158 shares, representing beneficial ownership of approximately 28.1% of RH's common stock. Friedman has also informed the company that he does not expect to sell additional shares at this time.

This is the first increase since November 25th.

Ferrari announces that it has signed a EUR350M unsecured committed revolving credit facility, or New RCF, intended for general corporate and working capital purposes. The New RCF, entered into with a group of twelve banks, has a five-year tenor with two further one-year extension options, exercisable on the first and second anniversary of the signing date on Ferrari's request and on each bank's approval for its participation. This facility replaces the EUR500M committed revolving credit facility due November 2020, which has been cancelled. The New RCF provides a lower cost of capital as compared to the prior facility and confirms the support that Ferrari receives from a large panel of international key relashionship banks. Its lower size reflects an overall evaluation of the optimal capital structure of the company going forward.

In an interview on CNBC's Mad Money, VMware (VMW) COO, customer operations Sanjay Poonen said: We are the Tesla (TSLA) of networking... Everything we do is for the long term... We're going to become the indispensable nervous system for companies... Two key words customers are talking about are migration and modernization...Our partnership with Dell (DELL) is better than ever... Our business in China is growing.

Puma Biotechnology announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2019 San Antonio Breast Cancer Symposium. Neratinib was approved by the FDA in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and is marketed in the U.S. as Nerlynx tablets. Nerlynx was granted marketing authorization by the European Commission for the extended adjuvant treatment of hormone receptor-positive HER2-positive early stage breast cancer in August 2018. The Phase II SUMMIT basket trial is a study to evaluate the safety and efficacy of neratinib administered daily to patients who have solid tumors with activating HER2 or HER3 mutations. The interim efficacy summary of the breast cohort that received neratinib in combination with trastuzumab and fulvestrant showed that for the 17 efficacy evaluable patients, 9 patients - 53% - experienced a confirmed objective response, all of which were classified as partial responses, and 10 patients - 59% - experienced clinical benefit. The median duration of response has not been reached and the median progression-free survival was 9.8 months. At the time of data cut-off, five patients continued to receive treatment. The most frequently observed adverse event was diarrhea. No patient permanently discontinued neratinib due to diarrhea.

G1 Therapeutics reported additional data from the Phase 1b/2a clinical trial investigating its oral CDK4/6 inhibitor lerociclib in combination with fulvestrant for the treatment of estrogen receptor-positive, HER2-negative breast cancer. Updated findings presented during a poster session at the 2019 San Antonio Breast Cancer Symposium, or SABCS, showed lerociclib, dosed without a drug holiday, has a differentiated safety and tolerability profile than observed in clinical trials with currently marketed CDK4/6 inhibitors. Preliminary efficacy findings were consistent with other CDK4/6 inhibitors used in combination with fulvestrant. The Phase 1b/2a trial is designed to evaluate the safety, tolerability and efficacy of lerociclib administered continuously in combination with fulvestrant as a treatment for ER+, HER2- breast cancer and identify the dose and schedule for future trials of lerociclib. Further investigation is ongoing, with longer-duration efficacy data required to determine the dose for future study in a Phase 3 clinical trial. The company expects to share an update in 2020.

NantHealth announced new breast cancer research findings presented during a poster session at the San Antonio Breast Cancer Symposium. The Symposium, held at the Henry B. Gonzalez Convention Center in San Antonio, TX from December 10-14, provides state-of-the-art information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers. NantHealth's presentation examined how results of the phase 3 KATHERINE clinical trial, first presented at SABCS 2018 and simultaneously published in the New England Journal of Medicine, affected treatment patterns and regimen selections among general medical oncologists in the U.S. before and after the results were publicly released. Data from NantHealth's Eviti Connect, an evidence-based treatment intelligence and web-based oncology decision support platform, was analyzed to determine the rate of requests for treatment authorization for adjuvant Ado-trastuzumab emtansine in patients with HER2-positive early-stage breast cancer. Study results indicated an immediate increase in T-DM1 use in the months following SABCS 2018. Based on data pulled from Eviti Connect, 95 cases would have received adjuvant T-DM1 in Q1 2019 after 0 in Q4 2018. When comparing T-DM1 and Trastuzumab use in the adjuvant breast cancer setting for HER2-positive patients, T-DM1 use since December 2018 increased and Trastuzumab use decreased as a percentage of treatment plan requests for adjuvant HER2-positive patients. "Our research clearly shows that presenting clinical data at a leading conference like the San Antonio Breast Cancer Symposium, and having the data simultaneously published in a medical journal, influences a broad audience of oncologists," said Sandeep "Bobby" Reddy, MD, Chief Medical Officer, NantHealth. "As results indicate an immediate increase in T-DM1 use in the months following SABCS 2018, leveraging multiple communications platforms is an important and effective way to relay practice-changing clinical data to practicing oncologists in the U.S. These forums and supporting scientific journals expose researchers, academics and medical professionals to the latest studies and ideas in the field for which they can apply to their practice."